- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential
U.S. Pharmaceuticals & Biotech Large Cap High Growth Potential
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
26 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NVAXNovavax | US$232.30 | -10.2% | 101.1% | US$17.3b | US$264.20 | P/S14.6x | E69.2% | n/a | ||
| LLYEli Lilly | US$233.73 | -2.6% | 53.3% | US$211.9b | US$264.58 | P/E34.9x | E20.6% | 1.5% | ||
| ALNYAlnylam Pharmaceuticals | US$187.48 | -1.1% | 43.1% | US$22.3b | US$182.50 | P/S32.4x | E70.8% | n/a | ||
| HZNPHorizon Therapeutics | US$106.07 | -1.3% | 36.1% | US$24.0b | US$130.27 | P/E46.2x | E55.2% | n/a | ||
| ZLABZai Lab | US$124.74 | -8.9% | 54.3% | US$11.9b | US$211.57 | P/S137.1x | E61.0% | n/a | ||
| CVACCureVac | US$56.39 | -17.9% | 6.6% | US$21.5b | US$80.11 | P/S182.5x | E54.3% | n/a | ||
| TXG10x Genomics | US$156.15 | -15.2% | 30.0% | US$17.3b | US$196.38 | P/S42.7x | E53.0% | n/a | ||
| INCYIncyte | US$73.44 | 1.0% | -18.8% | US$16.2b | US$103.31 | P/E48x | E36.9% | n/a | ||
| SGENSeagen | US$152.09 | 1.7% | -13.4% | US$27.7b | US$185.17 | P/E46.3x | E70.0% | n/a | ||
| PPDPPD | US$46.68 | 0.1% | 41.5% | US$16.4b | US$47.55 | P/E63.5x | E24.9% | n/a | ||
| BHCBausch Health Companies | US$28.16 | -1.6% | 62.0% | US$10.1b | US$35.50 | P/S1.2x | E62.1% | 0% | ||
| AVTRAvantor | US$42.59 | 1.7% | 89.4% | US$25.8b | US$44.94 | P/E96.7x | E26.8% | n/a | ||
| BIIBBiogen | US$299.21 | -0.3% | 8.7% | US$44.6b | US$423.24 | P/E23.2x | E22.2% | n/a | ||
| IQVIQVIA Holdings | US$258.55 | -1.0% | 61.1% | US$49.5b | US$275.67 | P/E81.6x | E26.0% | 0% | ||
| TECHBio-Techne | US$529.64 | 4.2% | 116.0% | US$20.8b | US$520.09 | P/E148.1x | E21.0% | 0.2% | ||
| BMRNBioMarin Pharmaceutical | US$77.27 | -3.5% | -1.4% | US$14.2b | US$111.25 | P/E16.9x | E47.1% | n/a | ||
| ILMNIllumina | US$449.88 | -2.0% | 51.0% | US$66.0b | US$460.56 | P/E85.8x | E27.4% | n/a | ||
| ICLRICON | US$263.04 | 1.6% | 45.7% | US$21.0b | US$248.17 | P/E57.6x | E17.5% | n/a | ||
| RGENRepligen | US$296.40 | 0.6% | 103.4% | US$16.3b | US$258.75 | P/E163.1x | E20.1% | n/a | ||
| VTRSViatris | US$13.73 | -3.9% | -15.0% | US$16.6b | US$19.38 | P/S1.1x | E54.0% | 3.2% | ||
| RPRXRoyalty Pharma | US$37.97 | -0.8% | -8.0% | US$23.1b | US$51.43 | P/E46.9x | E54.3% | 1.8% | ||
| BMYBristol-Myers Squibb | US$62.00 | -2.5% | 4.4% | US$137.8b | US$75.89 | P/S3.1x | E31.3% | 3.2% | ||
| ELANElanco Animal Health | US$32.41 | -3.4% | 18.5% | US$15.3b | US$38.67 | P/S3.4x | E55.4% | n/a | ||
| CRLCharles River Laboratories International | US$439.79 | -0.7% | 101.6% | US$22.2b | US$424.54 | P/E56x | E19.6% | n/a |